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Highlights 
- HCV E2E1Δ268-292 chimera, lacking the E1 putative fusion peptide, has been 
obtained 
- The mutant chimera has the conformational features of the full length one 
- HCVpp containing deleted E1 are not able to infect Huh7 cells 
- The involvement of the region 268-292 in membrane pore formation is 
suggested 
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Abstract 
We have obtained a chimeric protein containing the ectodomains of hepatitis C 
virus (HCV) envelope proteins but lacking the region 268-292 of E1. All its structural 
properties are coincident with those of the corresponding full length chimera. The 
deleted and entire chimeras were compared in terms of their membrane destabilizing 
properties. No differences were found in their ability to induce vesicle aggregation 
and lipid mixing but the deleted chimera showed a reduced capacity to promote 
leakage. The role of the deletion was also studied by obtaining HCV pseudoparticles 
(HCVpp). Both E1 and E2, and also the E1 deleted mutant, were incorporated into 
HCVpp to a similar level. However, HCVpp containing the E1 deleted protein are 
almost unable to infect Huh7 cells. These results point to the involvement of the 
region 268-292 in the formation of pores in the membrane necessary for the 
complete fusion of the membranes. 
 
Abbreviations 
HCV: hepatitis C virus 
HCVpp: hepatitis C virus pseudoparticles 
E2E1: chimeric protein containing the ectodomains of E2 and E1 HCV envelope 
proteins 
E2E1Δ268-292: chimeric protein containing the ectodomains of E2 and E1 but lacking 
the region 268-292 of E1 
CCA: Convex Constraint Analysis 
PG: egg yolk phosphatidylglycerol 
NBD-PE: N-(7-nitro-2,1,3-benzoxadiazol-4-yl)dimyristoylphosphatidyl-ethanolamine 
Rh-PE: N-(lissamine rhodamine B sulphonyl) diacylphosphatidyl-ethanolamine 
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ANTS: 8-aminonaphthalene-1,3,6-trisulphonic acid 
DPX: p-xylenebis-(pyridinium) bromide. LEL-CD81: large extracellular loop of CD 81 
 
Keywords: hepatitis C virus; viral envelope proteins; lipid-protein interaction; 
membrane fusion; protein spectroscopic properties. 
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1. Introduction 
Hepatitis C Virus (HCV) is the major cause of acute hepatitis and chronic liver 
disease, being the leading cause of liver transplantation in the developed world 
(Alter, 2006). Currently there is no vaccine available against HCV and the present 
standard therapy consists of interferon and ribavirin. However, only 10-20% of 
patients respond to interferon treatment and 54-56% to the combined therapy (Ronn 
and Sandstrom, 2008). Recently, new drugs are being used to treat HCV infection 
which has led to new treatments with a high efficacy but also with a high cost which 
precludes their use in a global scale (Kohli et al., 2014). Thus, it is clear the 
importance of obtaining a vaccine for HCV. In this search, a possible strategy would 
be to abolish the initial steps of the HCV infection. In this regard, HCV entry is a 
highly orchestrated process mediated by the viral envelope glycoproteins and several 
host factors (reviewed in (Ploss and Dubuisson, 2012)). 
HCV is an enveloped, positive-stranded RNA virus that belongs to the 
Hepacivirus genus of the Flaviviridae family (Lemon et al., 2007; Lindenbach and 
Rice, 2001). The HCV envelope glycoproteins, E1 and E2 are released from the 
polyprotein coded by the HCV genome after cleavage by host-cell endoplasmic 
reticulum proteases in positions 191/192, 383/384 and 746/747 of the polyprotein 
sequence, respectively (E1 corresponds to residues 192-383 and E2 to 384-746) 
(Mizushima et al., 1994). These glycoproteins play an essential role in virus entry into 
host cells by interacting with cell surface receptors and inducing fusion between the 
viral and cellular membranes (Bartosch et al., 2003; Nielsen et al., 2004).  
Studies concerning the entry mechanism carried out with HCV isolated 
envelope proteins are scarce. Both E1 and E2 have been proposed as candidates for 
the fusion process (Drummer et al., 2007; Flint et al., 2004; Yagnik et al., 2000). In 
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relation to the location of the regions involved in this process, some E1 and E2 
peptides with a potential fusogenic activity have been identified and characterized 
(Pacheco et al., 2006; Perez-Berna et al., 2006; Perez-Berna et al., 2009). A directed 
mutagenesis study with the HVCpp system has identified three important regions for 
the fusion (Lavillette et al., 2007). These are located in E1 (residues 272 to 287) and 
E2 (residues 419 to 433 and 597 to 620). These data suggest that different E1 and 
E2 regions can cooperate for the fusion process. In this sense, we have recently 
shown that a recombinant chimeric protein composed of E1 and E2 ectodomains 
possesses the membrane destabilization properties ascribed to a fusion protein 
(Tello et al., 2014). 
In order to shed light into HCV cell entry mechanism as well as into the protein 
and amino acid sequences involved on it, we have studied the fusion properties of a 
chimeric protein, E2661E1340Δ268-292 (E2E1Δ268-292), containing the E2 and the E1 
ectodomains connected by a small hydrophilic peptide but missing a region of E1 
which is supposed to contain a fusion peptide. The protein is able to accomplish the 
steps which are essential for fusion (Bentz et al., 1985). Also, HCVpp containing the 
deleted protein have been obtained and their infection capacity studied. The 
differences observed with respect to the intact recombinant protein point to the 
involvement of the region 268-292 in the fusion between the viral and cellular 
membranes. 
2. Materials and methods 
2.1. Plasmid constructs 
 The mutant cDNA E2661E1340Δ268-292 (hereafter E2E1Δ268-292) was obtained by 
the method described by Pogulis (Pogulis et al, 1996). The regions on both sides of 
the deletion were amplified separately by PCR, using the plasmid pAcGP67A-
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E2661E1340 (Tello et al., 2014) as template. The sequence of E1 and E2 corresponds 
to an HCV1 strain, genotype 1a (Accession number M62321). Primers GP67F (CTT 
GTC GGG TTT TCT CCC AGG CGC C) and GP67R (GGG TTT AAC ATT ACG GAT 
TTC), flanking the E2661E1340 cDNA in the pAcGP67-A plasmid, were used as 
external primers. Internal primers of the mutant had a complementary region of 18 
nucleotides, corresponding to the 9 final nucleotides and the first 9 nucleotides 
located before and after the deletion: 
 
Primer E1Δ268F:  CTT GTC GGG TTT TCT CCC AGG CGC C  
                              L265  V266  G267   F293  S294 P295  R296   R297 
Primer E1Δ268R:  GGG AGA AAA CCC GAC AAG CAG ATC G  
                              P295   S294  F293  G267   V266  L265   L264  D263 
  
After co-purification of both PCR products, E2E1192-267 and E1293-340, they were 
subjected to a second elongation PCR without primers in order to expand the area. 
Finally, a third PCR using the elongated sequence as template, and the 
oligonucleotides GP67F and GP67R as primers, was performed to amplify the 
mutant E2E1Δ268-292 cDNA fragment. This was subsequently digested with restriction 
enzymes BamHI and NotI and cloned in the pAcGP67-A baculovirus transfer vector 
(Pharmigen) to generate the recombinant plasmid pAcGP67-A-E2E1Δ268-292.  
2.2. Protein expression and purification 
E2E1Δ268-292 was expressed in baculovirus-infected High Five insect cells and 
the secreted protein was purified from the extracellular medium by Ni2+-nitrilotriacetic 
acid-agarose chromatography following the methodology previously described for the 
intact chimera E2E1 (Tello et al., 2015). 
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2.3. Protein analysis 
Protein concentration was determined spectrophotometrically from the 
absorbance at 280 nm and the extinction coefficient calculated from amino acid 
analysis. The absorption spectra were recorded on a Beckman DU-640 
spectrophotometer. The amino acid analysis of hydrolyzed aliquots was performed 
on a Beckman 6300 automatic amino acid analyzer.  
2.4. Circular Dichroism 
CD measurements were carried out at room temperature on a Jasco 
spectropolarimeter, model J-715. The secondary structure of the protein was 
evaluated by computer fit of the dichroism spectra according to Convex Constraint 
Analysis (CCA) (Perczel et al., 1991). 
2.5. Fluorescence spectroscopy 
Emission spectra were obtained using an SLM AMINCO 8000C 
spectrofluorimeter. Excitation was performed at 275 or 295 nm, and the emission 
spectra were recorded over the range 285-450 nm. The tyrosine contribution to the 
emission spectra was calculated as previously described (Tello et al., 2015). 
 
2.6. SDS-PAGE 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed according to Laemmli using 15% polyacrylamide gels (Laemmli, 
1970). The molecular mass of the protein bands was estimated by comparison with 
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protein markers of known molecular mass (Prestained SDS-PAGE Standards, Bio-
Rad). 
2.7. Western blotting 
After SDS-PAGE, proteins were transferred to nitrocellulose membranes 
(Hybond-ECL; Amersham) in 48 mM Tris-HCl pH 9.0, containing 39 mM glycine, 
0.0375% (w/v) SDS and 20% (v/v) methanol, for 1 h at 1 mA/cm2, by using a V20-
SDB apparatus (Scie-Plas). To detect proteins, membranes were incubated for 16 
h at 4 ºC either with a HRP-conjugated monoclonal anti-His antibody (Sigma) at a 
1:3000 dilution, with the A4 monoclonal anti-E1 antibody at a 1:1000 dilution or 
with a mixture of monoclonal antibodies anti-E2 ALP98 (1 ug/ml) and AP33 
(1:1000). All the anti-E1 and anti-E2 monoclonal antibodies were kindly provided 
by Dr. Jean Dubuisson, Institute Pasteur de Lille, France. In the case of 
incubations with anti-E2 and anti-E1 antibodies, membranes were washed and 
incubated for 1 h at room temperature with the corresponding secondary antibody, 
goat anti-mouse IgG (Sigma) at a 1:3000 dilution. Membranes were developed with 
ECL reagents (Amersham Life Sciences) and exposure using the program 
LaserJet3000.  
2.8. Enzyme Linked Immunosorbent Assay (ELISA) 
The reactivity of the recombinant proteins against human sera was tested as 
previously described (Tello et al., 2015). Six HCV-positive and two HCV-negative 
human sera, diluted between 1:100 and 1:500, were used. Bound antibodies were 
detected using HRP-conjugated anti-human IgG (Fc). Human sera were provided 
by Dr. Fernando Vivanco (Fundación Jiménez Díaz, Madrid, Spain).   
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For H53 ELISA assays, the same protocol was followed but with these 
exceptions but the plates were coated with 1 µg/well of purified protein. E2 was 
detected with H53 antibody at a 1:400 dilution and a goat anti-mouse-HRP 
conjugated antibody (Sigma) at a 1:3000 dilution. The monoclonal antibody H53 is 
conformation-dependent and was kindly provided by Dr. Jean Dubuisson (Institute 
Pasteur de Lille, France). 
2.9. LEL-CD81 binding assay 
Binding of E2E1 and E2E1Δ268-292 to the large extracellular loop of human 
CD81 (LEL-CD81) was determined as previously described (Ortega-Atienza et al., 
2014). Briefly, 0.3 μg of a glutathione S-transferase fusion protein containing the 
second extracellular region (EC2) of the LEL of human CD81 (Higginbottom et al., 
2000) were used to coat Nunc F96 Maxisorp, 96 well-plates. Then the entire or the 
deleted soluble chimera at different concentrations were added and incubated at 
room temperature for 2 h. CD81-bound protein was detected using a polyclonal 
antibody raised against isolated E2 ectodomain obtained in our laboratory followed 
by a goat anti-rabbit IgG (whole molecule)–peroxidase antibody  (1:3000) (Sigma). 
2.10. Vesicle preparation 
The vesicles used were prepared by sonication and extrusion in a Liposo 
Fast-Basic extruder apparatus (Avestin, Inc.) with 100-nm polycarbonate filters 
(Costar) as previously described (Tello et al., 2014). Lipid concentration was 
calculated based on their phosphorous content determined according to Barlett 
(Barlett, 1959).  
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2.11. Aggregation studies 
The aggregation of phospholipid vesicles induced by the addition of the 
recombinant proteins was followed by measuring the optical density at 360 nm 
(OD360) on a Beckman DU-640 spectrophotometer after incubation for 1 h at 37 ºC 
(Tello et al., 2014). The final phospholipid concentration was 0.14 mM. In all cases, 
controls of lipid vesicles in the absence of protein and protein in absence of lipid 
were obtained.  
2.12. Lipid mixing assay 
The fluorescent probe dilution assay (Struck et al., 1981), was employed to 
determine lipid mixing. All the conditions are coincident with those previously used 
for E1340E2661 (Tello et al 2014). The concentrations of the donor (NBD-PE) and 
acceptor (Rh-PE) were 0,11 and 0,06 μM, respectively. The efficiency of 
fluorescence resonance energy transfer (%RET) was calculated from the ratio of the 
intensities at 530 and 590 nm and the appropriate calibration curve which was 
obtained by using labeled vesicles containing 0,11 μM NBD-PE and variable 
concentrations of Rh-PE (between 0 and 0,075 μM). The final phospholipid 
concentration was 0.14 mM. 
2.13. Release of aqueous contents 
Leakage was determined by the ANTS/DPX leakage assay (Ellens et al., 
1985) as previously described (Tello et al., 2014). ANTS and DPX were co-
encapsulated in phospholipid vesicles at 12.5 mM and 45 mM respectively, in 10 mM 
Tris pH 7.2, 20 mM NaCl. The fluorescence spectra were measured in a SLM 
Aminco 8000C spectrofluorimeter. The excitation wavelength was set at 385 nm and 
the ANTS emission was monitored at 520 nm. The fluorescence of control vesicles 
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without protein was taken as 0% leakage while 100% was considered upon addition 
of 0.5% Triton X-100.  
2.14. Production and Detection of HCV pseudoparticles 
The HCV pseudoparticles (HCVpp) were obtained by a previously reported 
method (Bartosch et al., 2003). The plasmids pMLV-Gag-Pol, which allows the 
expression of retroviral structural proteins, and pMLV-Luc, which codes the 
luciferase, were kindly donated by Dr. Cosset of the École Normal Supérieure de 
Lyon. pcDNA-C132E1Δ268-292E2 was constructed following the procedure described 
above for plasmid pAcGP67-A-E2E1Δ268-292 using the same primers and the plasmid 
cDNA-C132E1E2 as template. The later was previously obtained in our laboratory by 
cloning directly the sequence of the HCV DNA into pcDNA3.1 plasmid between 
EcoRI and XbaI sites and contains the sequence which codes from residue 132 of 
the core protein and the entire E1 and E2 sequences including the transmembrane 
domains of both as they are in the original cDNA. In this case, the primers used for 
the ends are pENF-1 (F): 5’- GGT GGG AGG TCT ATA TAA -3’  and pcDNA-BGH 
(R): 5’- GGA GGG GCA AAC AAC AGA TG -3’, which hybridizes 159 bp before 
EcoRI an 30 bp after XbaI, respectively. 
To generate HCVpp, HEK 293T cells were transfected with expression vectors 
encoding the viral components. Briefly, the Gag-Pol packaging construct (8 μg), the 
luciferase vector construct (8 μg), and the glycoprotein-expressing construct (3 μg) 
DNAs were transfected into 8x105 HEK 293T cells seeded the day before in 10 cm 
plates using a calcium phosphate transfection protocol (CLONTECH Laboratories, 
Inc.), as described (Bartosch et al., 2003). The medium (10 ml/plate) was replaced 
16 h after transfection by 5.5 ml/plate with 10mM HEPES pH 7.0. Supernatants 
containing the pseudoparticles were harvested 24 h later, filtered through 0.45 μm 
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pore-sized membranes, and used in entry assays. Purified pseudoparticles were 
obtained by ultracentrifugation of 10 ml supernatants through a 1.5 ml 20% sucrose 
cushion in an SW 41 Beckman rotor (30000 rpm, 127 min, 4 ºC). The pellets were 
suspended in 20 μl loading buffer. Immunoblots of HCV expressing cell lysates and 
purified pseudoparticles were performed as described above. 
2.15. Infection Assays 
Huh7 target cells were seeded in 24 well plates at a density of 3x104 cells per 
well and incubated overnight at 37 ºC. 150 µl of supernatants containing the 
pseudoparticles were added to the cells and the plates were incubated for 4 h. The 
supernatants were removed and the cells were incubated in regular medium for 84 h 
at 37 ºC. The luciferase activity was then measured using the Bright-Glo luciferase kit 
(Promega) in a LB9507 luminometer (Thermo Fisher). The infectious titers are 
expressed as relative luminescence units. 
3. RESULTS 
3.1. Expression and purification of E2E1Δ268-292 
Fig. 1 shows a scheme of E2E1Δ268-292. The recombinant chimera would have 
432 amino acids, 278 corresponding to positions 384–661 of E2 ectodomain, 124 
corresponding to positions 192–340 of E1 ectodomain without the fusogenic peptide, 
and the rest being due to the cloning strategy, that is the spacer, the TEV sequence 
between E1 and E2 and the His tag. Following the methodology recently described 
for the entire E2661E1340 chimera (Tello et al., 2015), the mutant protein was 
expressed in High FiveTM insect cells transfected with the pAcGP67-A-E2E1Δ268-292 
plasmid. The protein was secreted to the extracellular media and subsequently 
purified by affinity chromatography using a Ni-nitrilotriacetic acid-agarose column. 
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The entire E2661E1340 was also purified and used as a control in all the experiments. 
Following this procedure, approximately 11 mg of highly pure E2E1Δ268-292 protein 
were obtained from 1 L of culture media. 
 
3.2. Biochemical characterization of E2E1Δ268-292 
The amino acid composition of the recombinant protein determined by amino 
acid analysis was coincident with that deduced from the cDNA sequence (data not 
shown). The extinction coefficient at 280 nm calculated from the absorption spectrum 
and using the protein concentration calculated from the amino acid analysis was 
21795 M-1cm-1. This value together with the absorbance at 280 nm allowed the 
determination of the protein concentration in all subsequent experiments. 
The recombinant protein behaves as a single band in SDS-PAGE in the 
presence of reducing agents. The calculated molecular mass, 64.4 kDa, was higher 
than that expected from the amino acid sequence (47.9 kDa) which indicates that the 
protein was highly glycosylated in insect cells (Fig. 2, lanes 3 and 4). In the absence 
of reducing agents, dimers, trimers and higher order oligomers are observed for both 
entire and deleted chimeras (Fig. 2a, lanes 1 and 2). Moreover, both proteins were 
recognized by a monoclonal anti-E1 antibody, a mixture of monoclonal AP33/ALP98 
anti-E2661 antibodies as well as a monoclonal anti-His antibody (Fig. 2b). 
The spectroscopic characterization of E2E1Δ268-292 was carried out by means 
of circular dichroism and fluorescence spectroscopies. The spectra were taken in 
parallel with E2E1 in order to check if deletion of 25 amino acids of E1 induced any 
conformational change. 
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The far-UV CD spectrum of both proteins showed a minimum at 208 nm, with 
a residue molar ellipticity of -7200 degree∙cm2∙dmol-1, indicative of a high level of 
aperiodic structure (Fig. 3a). Deconvolution of these spectra using the program CCA 
(Perczel et al., 1991) yielded the following percentages of secondary structure 
elements: α helix 13 and 14%, β sheet 48 and 45% and non-ordered structures 39 
and 41% for E2E1 and E2E1Δ268-292, respectively. Thus, both proteins showed a very 
similar secondary structure pattern, with a low helical content being the β-sheet the 
main ordered structure. These results show that there are no changes in terms of 
secondary structure when the amino acids 268-292 are deleted from the chimera 
E2E1.  
Fluorescence emission spectrum of E2E1Δ268-292, as well as of E2E1, showed 
a maximum at 333 nm upon excitation at 275 nm and 295nm (Fig. 3b). In both cases, 
the contribution of tyrosine residues to the emission fluorescence upon excitation at 
275 nm was very low, approximately 5 % (Fig. 3b). Thus, we can conclude that in 
both proteins the Trp residues are located in a very similar environment of relatively 
low hydrophobicity. The spectroscopic data indicate that the global structure of both 
proteins is similar and that the deletion of the putative fusion peptide is not relevant 
for the folding of the protein.  
3.3. Antigenic characterization of E2E1Δ268-292 
A panel of six HCV-positive and two HCV-negative human sera was used to 
assess the antigenic properties of E2E1Δ268-292 in comparison with E2E1. Both 
proteins were able to bind to antibodies present in the HCV-positive human sera (Fig. 
4, sera 1-6) at different levels, whereas they were not recognized by 
immunoglobulins from HCV-negative sera (Fig. 4, sera 7 and 8). The reactivity 
pattern was very similar in both cases. However, it must be noted that the mean 
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signal obtained with E2E1Δ268-292 is about 37% higher than the observed with E2E1. 
This result could indicate that the antigenic determinants are more exposed in the 
recombinant protein with the putative fusogenic peptide deleted. Anyhow, it is clear 
that the overall reactivity is maintained.  
On the other hand, the reactivity of both proteins with the anti-E2 
conformation-dependent H53 monoclonal antibody was very similar (Fig. 4, inset).  
Again, these results suggest that both, E2E1 and E2E1Δ268-292, possess very similar 
conformations with some differences in the degree of exposure of some epitopes. 
Moreover, both E2E1 and E2E1Δ268-292 were able to bind to CD81 in a concentration 
dependent manner, being the reactivity of both proteins very similar. 
3.4. Membrane destabilization properties of E2E1Δ268-292 
The ability of the recombinant E2E1Δ268-292 protein to induce vesicle 
aggregation of PG liposomes was monitored by measuring the increase in the optical 
density at 360 nm (ΔOD360) as a result of the enlargement in vesicle size upon 
incubation with different concentrations of E2E1Δ268-292 and E2E1. The results 
obtained for the different phospholipid/protein ratios at pH 5.0 and pH 7.0 are 
depicted in Fig. 5(a). E2E1Δ268-292 was able to generate slightly higher levels of 
aggregation than E2E1 showing the same pH and concentration dependence. The 
observed pH dependence would be a consequence of the viral fusion taking place at 
acidic pH in the endosomes (Lavillette et al., 2006). Thus, the region between 268 
and 292 in E1 seems not to be relevant for the aggregation process. 
 As it is observed in Fig. 5(b), both E2E1Δ268-292 and E2E1 proteins were also 
able to induce lipid mixing of PG vesicles, both at pH 7.0 and 5.0, being the effect 
produced at neutral pH much lower than that observed at acidic pH. At pH 5.0, 
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%RET decreased from 63%, in the absence of protein, to around 18% at a 
protein/lipid ratio of 20 x 10-3. This value corresponds to a 3.5 fold dilution in acceptor 
surface density. This fact together with the considerable increase in vesicle size 
stated above would support the almost complete fusion of the vesicles (Ellens et al., 
1985). When neutral pH was used, the energy transfer only diminished from 60% to 
42-47% which again points out for a fusion process taking place at the endosomes. 
Since the levels reached by both proteins are very similar, the putative fusion peptide 
would not have either a role in this step of the fusion process. 
 Fig. 5(c) shows the leakage induced by the recombinant proteins when they 
were added to PG vesicles at pH 5.0. Both E2E1 and E2E1Δ268-292 were able to 
promote the release of internal contents of the vesicles in a dose-dependent manner. 
However, the putative fusion peptide seems to have an effect in this fusion step since 
a difference in the protein concentration needed to attain the same level of leakage 
was observed. Thus, when E2E1 was employed, the 80% of leakage was reached at 
a protein/phospholipid ratio of 0.25 x 10-3 but when E2E1Δ268-292 was used, a protein 
concentration 15 times higher was needed to attain similar leakage levels.  
3.5. Entry capacity of HCVpp containing the mutant protein 
The role of deleting the E1 putative fusion peptide on the function of the 
envelope glycoproteins has been studied by means of HCVpp. They were obtained 
by transforming HEK 293T cells with the plasmid pcDNA-C132E1Δ268-292E2. Also, 
HCVpp without envelope proteins and those containing C132E1E2 were obtained and 
used as negative and positive controls, respectively. The expression and integration 
of the envelope proteins were evaluated by immunodetection both in lysed HEK 293T 
transformed cells and in purified particles analyzed by SDS-PAGE, respectively (Fig. 
6). The expression of both glycoproteins is obvious in transfected cells with both 
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plasmids but no bands are observed when the cells were transformed with the 
plasmid lacking the envelope proteins (Fig. 6b). To detect the presence of E1 and E2 
in isolated pseudoparticles, they had to be concentrated by ultracentrifugation. It can 
be seen that both glycoproteins are incorporated into HCVpp of both types and that 
the levels of expression are very similar (Fig. 6a). 
 The HCVpp were used to infect Huh7 cells. The luminescence produced by 
the luciferase after four days of incubation was used to quantify the infectivity level 
because only the pseudoparticles able to enter the cells would lead to a 
luminescence signal. When the cells were infected with HCVpp C132E1Δ268-292E2 the 
signal decreased to 4.8±1.1 as compared to the positive control (100.0±1.0). The 
luminescence signal obtained with HCVpp containing no envelope proteins was 
1.8±1.0. Since the expression and incorporation levels are similar the decrease of the 
infectivity could be attributed to the absence of the putative fusion peptide in particles 
produced in pcDNA-C132E1Δ268-292E2 transfected cells. 
4. DISCUSSION 
The difficulty of expanding HCV in cell culture has hampered for many years 
functional studies on HCV infection. The cellular mechanism of HCV entry has been 
studied using HCV pseudoparticles (HCVpp), infectious retroviral particles with HCV 
envelope proteins on the surface, and the cell culture model which allows the 
production and propagation of virus in cell culture (HCVcc) (Lindenbach et al., 2005; 
Wakita et al., 2005; Zhong et al., 2005). Reports using both HCVpp and HCVcc 
models have evidenced the pH sensitivity of HCV entry (Blanchard et al., 2006; Haid 
et al., 2009; Lavillette et al., 2006). Several studies suggest that HCV enters cells by 
clathrin-mediated endocytosis (Blanchard et al., 2006) and that fusion occurs in the 
early endosomes (Meertens et al., 2006). Furthermore, the acidic pH of endosomes 
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triggers the fusion process probably by inducing conformational changes in the 
envelope proteins (Blanchard et al., 2006; Koutsoudakis et al., 2006; Meertens et al., 
2006; Tscherne et al., 2006). 
The exposed nature of the hepatitis C virus envelope proteins makes them 
good candidates to participate in the fusion between the viral and cellular 
membranes. In fact, bioinformatics studies suggest that both E1 and E2 are class II 
fusion proteins (Garry and Dash, 2003; Yagnik et al., 2000) although recent structural 
studies of E1 and E2 fragments do not support this idea (El Omari et al., 2014; Khan 
et al., 2014; Kong et al., 2013). However, several studies suggest the involvement of 
both E1 and E2 in the process (Drummer et al., 2007; Flint et al., 2004; Yagnik et al., 
2000). On the other hand, the data concerning the location of the regions with 
fusogenic properties are limited and entail amino acid sequences from both E1 and 
E2 glycoproteins. Thus, several membrane active regions have been found in E1 and 
E2 which suggest that both proteins participate in the fusion process (Pacheco et al., 
2006; Perez-Berna et al., 2006). A peptide derived from the 265-296 amino acid 
sequence of E1 has been synthesized and its membrane destabilizing properties 
determined (Perez-Berna et al., 2009). Other group has identified six regions in E1 
and E2 with features of fusion peptides and has proposed that at least the regions 
270-284 of E1 and 416-450 and 600-620 of E2 participate in the membrane fusion 
process (Lavillette et al., 2007). Mutation analysis of hydrophobic residues in the 
putative fusogenic region of E1 has revealed that only the F285A mutant abolished 
viral entry whereas other mutations did not affect or only partially inhibited viral entry 
(Drummer et al., 2007). Finally, it has been reported that specific residues between 
positions 264 and 290 within E1, but not the structure, are responsible for fusion (Li 
et al., 2009). 
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Few studies on the involvement of isolated envelope proteins in HCV entry 
mechanism have been published. In an effort to contribute solutions to the location of 
the fusion region, we have obtained a chimeric protein, E2E1Δ268-292, where one of the 
putative fusion peptides has been eliminated. The amino acid sequence analysis of 
E1 and E2 indicates that they are type-I transmembrane proteins, highly 
glycosylated, with an N-terminal ectodomain and a C-terminal hydrophobic domain 
anchoring these glycoproteins to the membrane. Moreover, it has been shown that 
E1 folding is dependent on E2 co-expression (Michalak et al., 1997; Patel et al., 
2001), and that E2 folding is also dependent on E1 co-expression (Brazzoli et al., 
2005; Cocquerel et al., 2003). 
 We have considered the presence of both ectodomains in a single 
polypeptide chain because heterodimerization of the E1/E2 glicoproteins has been 
described to be mandatory for fusion of viral and host cell membranes during the 
infection of HCV (Ciczora et al., 2007; Op De Beeck et al., 2001; Op De Beeck et al., 
2004). Also, the presence of both proteins is necessary to form infectious 
pseudoparticles (Sandrin et al., 2005). We have previously obtained a chimera, 
E1340E2661, composed of the ectodomains of E1 and E2 (Tello et al., 2010) and 
shown that it possesses fusogenic properties (Tello et al., 2014). Moreover, we have 
also shown that the two domains can be permuted so that the recombinant protein 
E2661E1340 is structurally indistinguishable of its counterpart E1340E2661 but the 
exchange process leads to a 4 times increase of the expression yield (Tello et al., 
2015). Also, the properties of E2E1 shown throughout this paper confirm the identity 
of both original and permuted chimeras in terms of membrane destabilization 
properties. Thus, we have used the later to obtain a mutant where the E1 fusogenic 
region has been deleted. Based on the interfacial hydrophobicity (Wimley and White, 
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1996) and hydropathicity profiles (Kyte and Doolittle, 1982) we decided to delete the 
region 268-292 that, although does not exactly coincide with published regions, it 
contains the putative E1 fusogenic stretch described by others (Lavillette et al., 2007; 
Perez-Berna et al., 2009). 
The properties of the mutated chimera E2E1Δ268-292 are practically coincident 
with those of the entire protein. Thus, all the spectroscopic features such as 
dichroism and fluorescence spectra revealed that the protein is correctly folded and 
has the structure of a native protein with the same properties than the complete 
chimera E2E1. With respect to the oligomerization properties, the mutated and entire 
proteins behave as dimers, trimers and higher order oligomers in the absence of 
reducing agents. Although it has been described that the large covalent E1E2 
complexes which can be observed in PAGE-SDS gels correspond to nonfunctional 
aggregates (Op De Beeck et al., 2004), more recent studies, using the HCVcc 
system demonstrated that the large E1E2 disulfide-linked complexes maintain a 
native conformation (Vieyres et al., 2010). Then, the disulfide-bridge oligomerization 
of E2E1 and E2E1Δ268-292 seems to be compatible with the maintenance of its native 
properties. 
 Antigenic studies revealed that both, the complete chimera and the mutated 
one are equally recognized by antibodies present in HCV positive sera. For most of 
the sera, the deletion is accompanied by a slightly higher degree of exposure of the 
antigenic determinants which gives rise to higher absorbance values in the assay 
performed. Anyway, all these characteristics point to a slight modification of the 
overall structure as a consequence of the deletion and allow us to compare both 
proteins in terms of membrane destabilizing properties and extract conclusions about 
the role of the region 268-292 of E1 in the initial steps of the infective cycle. 
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As expected from previous reports (Haid et al., 2009; Lavillette et al., 2006; 
Tello et al., 2014), the aggregation and lipid mixing results indicate that the fusion 
process is pH dependent and the attained levels can be decreased by increasing the 
ionic strength of the medium (data not shown). On the other hand, no differences 
were noted when comparing the ability of E2E1 and E2E1Δ268-292 to induce 
aggregation and lipid mixing. However, when leakage assays were compared, a 
drastic reduction of the capacity to disrupt the membrane was observed. A 10 times 
higher protein concentration is needed to attain results comparable to those of the 
entire chimera. As pointed out above, this reduction of the disruption ability can be 
attributed to the deletion of the fusion peptide itself and not to a change in the 
structure as a consequence of the elimination.  
The role of the deletion on the function of the envelope proteins was studied 
by obtaining HCVpp which could give us some clue about the involvement of the 
removed peptide in the entry mechanism. Both E1 and E2, and also the E1 deleted 
mutant, were incorporated into the pseudoparticles to a similar level. However, 
HCVpp C132E1Δ268-292E2 are almost unable to infect Huh7 cells. Since the isolated 
E2E1 and E2E1Δ268-292 proteins bind to the CD81 receptor, this diminution could be 
due to the reduced capacity of the mutant protein to disrupt the membrane as 
revealed by the leakage assay. In fact, it has been described that the fusion process 
comprise several steps: membrane apposition which destabilize the interface, 
formation of the hemifusion intermediate where mixing of the lipids can occur and 
finally the formation of pores and full collapse of the membranes (Sapir et al., 2008). 
If the mutant chimera is not able to produce pores in the membrane, this protein 
would not be able to fuse membranes and hence the pseudoparticles obtained with 
this protein would not have the capability to enter and infect cells. Anyhow, since 
23 
 
aggregation and lipid mixing are not changed when E1 peptide fusion is missing, 
some other stretches in E1 and/or E2 must be involved. In this sense, fusion must be 
a really complex process with the participation of several regions such it has been 
described in other viruses (Peisajovich and Shai, 2003) and even in HCV (Lavillette 
et al., 2007). 
Therefore, the data presented here point to the involvement of the region 268-
292 of E1 in the fusion process. In this sense it is worth mentioning that the deleted 
E1 fusion peptide amino acid sequence of the different HCV genotypes has common 
characteristics .Thus, of the 25 amino acids, 13 are fully conserved or changed by 
others with similar properties. Moreover, the distribution of small and hydrophobic 
amino acids as well as sulfhydryl, hydroxyl and glycine residues is very similar. 
Finally, these data also validate the use of the E2E1 chimera in the localization of the 
regions responsible for the fusion of the viral and cellular membranes and makes it a 
good candidate to be used as an immunogen in the control of the viral infection since 
it could produce antibodies that would block the entry of HCV into the hepatocytes. 
. 
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Figure Captions 
Fig. 1. Schematic representation of E2E1Δ268-292. The E1 and E2 proteins are showed 
in white, and the spacer-TEV region in grey. The TEV protease recognition site 
(ENLYPQ) is shown. The arrow indicates the cleavage site. The deleted amino acids 
are noted with an empty triangle. The 6xHis tag at the N terminal end is shown in 
black. 
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Fig. 2. Molecular characterization of E2E1Δ268-292. (a) SDS–PAGE of E2E1 (lanes 1 
and 3) and E2E1Δ268-292 (lanes 2 and 4) purified recombinant proteins in the absence 
(lanes 1 and 2) and presence (lanes 3 and 4) of 5% -mercaptoethanol. The position 
of the molecular mass markers is indicated. The gel was stained with Coomassie 
Brilliant blue R-250. Lanes 1 to 4 belong to the same gel but some empty lanes, 
which were included to avoid diffusion of the reducing agent, have been removed for 
simplicity. (b) Western blot analysis of purified E2E1 and E2E1Δ268-292 using anti E2 
(AP33+ALP98), anti E1 (A4) and anti His antibodies. 
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Fig. 3. Spectroscopic characterization of E2E1 and E2E1Δ268-292. (a) Far-UV CD 
spectra at pH 8.0. The protein concentration was 0.1 mg/ml. Spectra were recorded 
five times, averaged and corrected for buffer contributions. Data are expressed as 
mean residue molar ellipticity. (b) Fluorescence emission spectra at pH 7.0 upon 
excitation at 275 nm. The Tyr contribution is also shown. The protein concentration 
was 0.05 mg/ml. The buffer employed was 20 mM Tris pH 8.0, 50 mM NaCl and its 
contribution was always subtracted. Spectra were collected at room temperature. 
The spectra shown are representative of those obtained for three different protein 
preparations. 
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Fig. 4. Reactivity of E2E1 and E2E1Δ268-292 against HCV-positive (1-6) and negative 
(7 and 8) human sera. 96-well plates were coated with 100 ng of purified 
recombinant protein/well. (Inset) Reactivity of E2E1 and E2E1Δ268-292 against H53 
conformation-dependent monoclonal antibody. Averages and standard deviations of 
three independent experiments are shown. 
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Fig. 5. Aggregation (a), lipid mixing (b) and leakage (c) of PG vesicles induced by 
E2E1 and E2E1Δ268-292. The final phospholipid concentration was 0.14 mM. (a) The 
increase of the optical density at 360 nm (ΔOD360) was measured after incubation of 
vesicles in medium buffer at pH 5.0 or pH 7.0. (b) Increasing concentrations of each 
protein were added to a 1:9 mixture of labeled (0,11 μM NBD-PE and 0,06 μM Rh-
PE) and unlabeled PG vesicles hydrated in medium buffer at pH 7.0 or 5.0. (c) 
Increasing concentrations of both proteins were added to vesicles loaded with ANTS 
and DPX in medium buffer at 5.0. Averages and standard deviations of three 
independent experiments are shown. 
 
  
32 
 
Fig. 6. Immunodetection of E1 and E2 envelope glycoproteins in purified HCVpp (a) 
and transfected HEK 293T cells (b). E1 was detected with A4 monoclonal antibody 
and E2 with a mixture of AP33 and ALP198 monoclonal antibodies. Gag protein was 
detected with CRL1912 rat antibody.  
 
